Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours. by Custers, Lars et al.
ARTICLE
Somatic mutations and single-cell transcriptomes
reveal the root of malignant rhabdoid tumours
Lars Custers 1,2,14, Eleonora Khabirova 3,14, Tim H. H. Coorens 3,14, Thomas R. W. Oliver 3,4,5,
Camilla Calandrini1,2, Matthew D. Young3, Felipe A. Vieira Braga 6, Peter Ellis3, Lira Mamanova 3,
Heidi Segers 7, Arie Maat1, Marcel Kool1,8,9, Eelco W. Hoving 1, Marry M. van den Heuvel-Eibrink 1,
James Nicholson4,10, Karin Straathof 11,12, Liz Hook4,5, Ronald R. de Krijger1,13, Claire Trayers 4,
Kieren Allinson4, Sam Behjati 3,4,10,15✉ & Jarno Drost 1,2,15✉
Malignant rhabdoid tumour (MRT) is an often lethal childhood cancer that, like many pae-
diatric tumours, is thought to arise from aberrant fetal development. The embryonic root and
differentiation pathways underpinning MRT are not firmly established. Here, we study the
origin of MRT by combining phylogenetic analyses and single-cell mRNA studies in patient-
derived organoids. Comparison of somatic mutations shared between cancer and sur-
rounding normal tissues places MRT in a lineage with neural crest-derived Schwann cells.
Single-cell mRNA readouts of MRT differentiation, which we examine by reverting the genetic
driver mutation underpinning MRT, SMARCB1 loss, suggest that cells are blocked en route to
differentiating into mesenchyme. Quantitative transcriptional predictions indicate that com-
bined HDAC and mTOR inhibition mimic MRT differentiation, which we confirm experi-
mentally. Our study defines the developmental block of MRT and reveals potential
differentiation therapies.
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Malignant rhabdoid tumours (MRT) are soft tissue can-cers that predominantly affect infants. Although theymay arise in any body part, MRT usually form in iso-
lation or synchronously in the kidney and the brain (where they
are referred to as atypical teratoid/rhabdoid tumours (AT/RT)).
MRT, especially metastatic MRT, remain one of the most lethal
childhood cancers, even following intense multimodal treatment.
The sole driver event of MRT is the occurrence of biallelic
mutations in the genes encoding SMARCB1 (INI1, 95% of cases)
or SMARCA4 (BRG1, 5% of cases), the core subunits of the
SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin-
remodelling complex1–3. In about one-third of cases, one of the
variants is present in the germline, thus predisposing children to
the development of MRT4.
Like most childhood cancers5, MRT are thought to arise during
embryogenesis, a notion that has recently been substantiated in
studies of mouse models of Smarcb1 loss. Rhabdoid tumours,
albeit the majority being AT/RT, only developed in these mice
when Smarcb1 was inactivated during very early embryogenesis,
but not at later fetal stages or in adult animals. Renal MRT were
never observed6. Analyses of bulk, and more recently of single-
cell transcriptomes, suggest that MRT retain an overall fetal
transcriptome with neural as well as mesenchymal signals7–10.
These findings suggest as a plausible source of rhabdoid tumours
the ectoderm-derived neural crest, which is uniquely capable of
generating cell types across the boundaries of the germ layers,
mesoderm and ectoderm.
The fetal origin of MRT may be exploitable therapeutically by
promoting differentiation of MRT along developmental path-
ways. The possibility of devising differentiation treatments for
childhood cancer has recently gained traction with the advent of
high-throughput single-cell assays5,10–12. Single-cell tran-
scriptomic readouts enable precise, comprehensive and quanti-
tative comparisons of cancer cells to the transcriptional changes
underpinning normal cellular development, thus potentially
revealing therapeutic avenues for promoting cellular maturation.
Here, we define the developmental root of MRT and reveal
opportunities for differentiation therapy, combining phylogenetic
analyses of tumours and surrounding normal tissues, single-cell
mRNA readouts, and perturbation experiments in patient-derived
MRT organoids.
Results
Malignant rhabdoid tumours are phylogenetically related to
neural crest-derived tissues. The starting point of our investi-
gation were phylogenetic analyses of MRT, to establish whether
the origin of MRT lies in the neural crest in humans. We have
previously shown that it is feasible to reconstruct the develop-
mental relationship between childhood tumours and normal tis-
sues from the distribution of somatic mutations across tissues13.
Applying these principles to MRT, we used DNA whole-genome
sequencing (WGS) to study two cases of MRT along with cor-
responding normal tissues.
First, we examined tissue obtained from a child presenting with
the most common type of extracranial rhabdoid tumour, renal
MRT. The child carried a pathogenic germline SMARCB1
mutation. We performed WGS of tumour (n= 2), blood cells,
kidney parenchyma, and renal hilar tissue (n= 2) (Fig. 1a,
Supplementary Table 1). Using an established variant calling
pipeline13–16, we determined somatic variants in each tissue, from
which we derived phylogenetic relations between tumour and
normal tissues. The possibility of observing shared mutations due
to tumour contamination was addressed by histological examina-
tion and by quantitative assessment through a mixture model
(“Methods” section). The key finding in this first case was that
some, but not all somatic mutations of the tumour, were present
in hilar tissues, occupied by ganglion cells and Schwann cells
(Fig. 1a, b, Supplementary Fig. 1). Both these cell types are
derived from the neural crest. However, there were no shared
somatic mutations between tumour and blood or kidney
parenchyma, bar ubiquitous early embryonic mutations (Fig. 1a,
Supplementary Fig. 1). These findings place MRT on an
ectodermal, neural crest-derived lineage with Schwann cells,
distant from mesodermal blood and kidney parenchymal
lineages.
Examining shared mutations between tumour and hilar tissues
more closely, we found that one hilar biopsy, occupied mainly by
ganglion cells, shared only a small number (n= 6) of variants
with the tumour, whereas the second, composed of Schwann cells,
shared 175 mutations with the tumour (Fig. 1a, b, Supplementary
Data 1) including copy number-neutral loss of heterozygosity of
SMARCB1 (Supplementary Fig. 2). To verify this finding, we
performed immunohistochemistry of the SMARCB1 protein,
INI1 (Fig. 1c). As predicted from the distribution of mutations,
the first hilar biopsy showed only occasional INI1 negative cells,
consistent with a heterozygous germline mutation of SMARCB1.
By contrast, the Schwann cells of the second hilar biopsy, which
should have stained ubiquitously and intensely positive for INI1
(Fig. 1d), did not exhibit INI1 staining (Fig. 1c), consistent with
biallelic loss of SMARCB1 predicted from the somatic genome of
this tissue.
Next, we examined the tissues obtained post mortem from a
child, who succumbed to an MRT of the cervical spine. The
tumour bulk was situated ventrally in the extradural space. The
child did not carry germline SMARCB1 mutations. No early
mosaic (i.e. present in blood) variant affecting SMARCB1 was
discovered in this patient. We studied tumour tissue along with
nine normal tissues: skin (n= 2), fat (n= 2), muscle (n= 2),
blood, dorsal, and ventral nerve roots (Fig. 1e, Supplementary
Table 1). Pursuing the same analyses as before, we found that the
tumour was somatically related to neural crest-derived Schwann
cells sampled in nerve roots (Fig. 1e, f, Supplementary Fig. 1,
Supplementary Data 1), but not to any other normal tissue. The
clonal composition underlying this phylogenetic relation was
complex. Based on variant allele frequencies and distribution of
mutations, we were able to discern four clones (Fig. 1g), two of
which were shared between Schwann cells and tumour. In
addition, the tumour and Schwann cell lineages possessed a
private clone each, alluding to a sustained potential of tumour
and Schwann cells for subclonal diversification. Analysis of copy
number variants (CNVs) revealed a biallelic loss of SMARCB1 in
tumour and both nerve roots (Fig. 1e, Supplementary Fig. 2,
Supplementary Data 1), which again we were able to validate
through INI1 staining. INI1 negative Schwann cells were more
readily found in the ventral root, consistent with the larger clone
sizes in this tissue (~40% vs. ~20%, Fig. 1h, i). Together, these
observations provide the most direct evidence yet that human
MRT is phylogenetically related to the neural crest lineage and
firmly places its origin in fetal life.
SMARCB1 reconstitution drives MRT differentiation. To
establish the differentiation stage of MRT within neural crest
development, we studied the consequences of reversing the loss
of SMARCB1, the principal genetic driver of MRT. As a model
of MRT, we utilised patient-derived MRT organoids, which
have been shown to faithfully recapitulate the genetic, tran-
scriptional, and epigenetic features of primary MRT tissue17.
We reconstituted SMARCB1 expression in three MRT organoid
cultures17 (60T, 78T and 103T; Supplementary Table 2) by
lentiviral transduction with either a control or SMARCB1
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21675-6
2 NATURE COMMUNICATIONS |         (2021) 12:1407 | https://doi.org/10.1038/s41467-021-21675-6 | www.nature.com/naturecommunications
expression plasmid (Fig. 2a, Supplementary Fig. 3a). DNA
methylation profiles of MRT organoids resembled those of
primary MRT tissue, irrespective of SMARCB1 status (Sup-
plementary Fig 3b). Reconstitution of SMARCB1 expression
induced a proliferation arrest in all MRT cultures (Supple-
mentary Fig. 3c) with a morphological transformation of cells
(Fig. 2b, Supplementary Fig. 4a, c). While both 60T and 103T
transformed from a grape-like to a neural- or fibroblast-like
morphology with long extensions protruding from the cell
body, 78T stopped proliferating without an apparent mor-
phological change. To assess the transcriptional profiles
underpinning these phenotypic changes, we subjected organoid
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cultures, without and with SMARCB1 re-expression, to single-
cell mRNA sequencing (10× Genomics Chromium platform,
n= 16,133 cells post filtering). Cell cycle profiles generated
from single-cell transcriptomes confirmed the growth arrest
induced by SMARCB1, with 78T showing the least penetrant
effect (Supplementary Fig. 3d). UMAP clustering revealed that,
as expected, most transcriptomic variance of MRT single cells
can be explained by donor, as cells first separate by patient line
(Supplementary Fig. 3e). After transduction, the majority of
cells expressing SMARCB1 segregated into independent cell
clusters for each patient line (Fig. 2c, Supplementary Fig. 5a–c).
This segregation was not explained by batch effects of indivi-
dual cultures, as unsuccessfully transduced cells co-clustered
with cells from cultures transduced with the control plasmid
(Supplementary Fig. 3f). As our phylogenetic analyses revealed
that MRT are neural crest-derived (Fig. 1), we subsequently
assessed the similarity of MRT cells with and without
SMARCB1 re-expression relative to single-cell signals of
(murine) neural crest development18 using logistic regression12
(Fig. 2a). At baseline (i.e. no SMARCB1 re-expression), MRT
organoid transcriptomes primarily resembled mesenchymal
and neural cells (Fig. 2d, Supplementary Fig. 3g), as previously
shown7,8,10. In addition, each individual patient line exhibited
different signals of neural crest differentiation stages (Fig. 2d,
Supplementary Fig. 3g). Patient lines 60T and 103T primarily
resembled mesenchymal cells, whereas 78T exhibited a more
neural signal. Examining cellular mRNA profiles upon
SMARCB1 reconstitution, MRT cells appeared consistently
more differentiated. That is, they resembled their normal
counterpart more strongly, as similarity to most neural crest
cell types increased (Fig. 2d, Supplementary Fig. 3g). Further
assessment of cell type similarity showed that SMARCB1
reconstitution promotes a neural to mesenchyme conversion
that is consistent among all three MRT organoid cultures
(Fig. 2e). These results were validated using a second inde-
pendent mouse single-cell mRNA reference of early neural and
mesenchymal cell types19 (Supplementary Fig. 3h). In agree-
ment, analysis of neural crest differentiation genes showed a
significant upregulation of mesenchymal markers (Fig. 2b, f, g,
Supplementary Fig. 4b–d, Supplementary Data 2). Additional
cell typing was performed for each single-cell cluster separately
to evaluate intra-organoid heterogeneity (Supplementary
Fig. 5a–f, Supplementary Data 2), showing that single-cell
clusters exhibited variable neural crest differentiation signals.
However, SMARCB1+ clusters consistently induced a relative
gain of mesenchymal differentiation signal, with the exception
of minor cluster 60T_S2, which retained a more neural iden-
tity. Altogether, our findings place MRT on a developmental
trajectory of neural crest to primarily mesenchyme conversion,
which is promoted by SMARCB1 reconstitution.
Mimicking SMARCB1 reconstitution pharmacologically.
Reconstitution of SMARCB1 to drive differentiation of MRT
would appear to be an attractive, non-cytotoxic treatment strat-
egy. However, reinstating SMARCB1 expression genetically in
children is not feasible at present. An alternative strategy is to find
agents that mimic the changes induced by SMARCB1 re-
expression. Using bulk mRNA-seq, we defined a SMARCB1+
transcriptional programme based on genes upregulated upon
SMARCB1 re-expression in our three MRT organoid cultures
(Supplementary Fig. 6a, Supplementary Data 3). We could vali-
date the SMARCB1+ programme in MRT tissue and found a
positive correlation with SMARCB1 expression levels in normal
tissues (Supplementary Fig. 6b). To explore therapeutic avenues,
we searched a publicly available perturbation data base20 for
drugs that induce expression changes of SMARCB1 reconstitution
(Fig. 3a). This analysis identified a variety of HDAC and mTOR
inhibitors (Supplementary Fig. 6c) as the top hits. Interestingly,
HDAC inhibitors have previously been identified for treatment of
rhabdoid tumours by orthogonal approaches21. We tested the
phenotypic and transcriptional effects of these agents, alone or in
combination, across the three MRT organoid cultures. HDAC
inhibition alone induced a morphological transformation akin to
SMARCB1 reconstitution (Fig. 3b, Supplementary Fig. 7a). Fur-
thermore, there was a significant correlation between gene
expression changes of bulk culture transcriptomes of SMARCB1
re-expression and HDAC inhibition (Fig. 3c, Supplementary
Fig. 6d). Inhibition of mTOR signalling primarily constrained
organoid growth, which, however, was readily reversible by drug
washout (Fig. 3f, g). Combination of HDAC and mTOR inhibi-
tion induced the phenotypic and transcriptional changes of
SMARCB1 reconstitution/HDAC inhibition as well as a marked
proliferation arrest (Fig. 3b, c, Supplementary Fig. 7a). The action
of HDAC and mTOR inhibition was synergistic, as corroborated
by assessment of the two drugs in dose-response matrices
(Fig. 3d, e, Supplementary Fig. 8a). Furthermore, the combined
effects of the drugs on viability were more durable than single-
agent treatment. On its own, anti-proliferation effects of each
drug were readily reversible upon washout (bar HDAC inhibition
in MRT organoid 103T). By contrast, combination treatment had
more lasting effects on proliferation in all tested MRT organoid
cultures (Fig. 3f, g, Supplementary Fig. 7b). While regrowth of
60T and 103T was completely diminished after drug washout,
78T showed minor regrowth, which could relate to the remnant
proliferating cells that were also observed upon SMARCB1
reconstitution (Supplementary Fig. 3d). To determine whether
MRT are in particular sensitive to HDACi and mTOR inhibition,
we tested the sensitivity of normal kidney organoids22 to both
drugs. Normal kidney organoids were significantly more resistant
to single agents as well as combination treatment, and in contrast
to MRT, showed significant regrowth upon washout of drug
combination (Fig. 3f, g, Supplementary Figs 7b, 8b–d). Mechan-
istically, the longevity of the effects of combined HDAC and
mTOR inhibition may be mediated through interference with
MYC, as MYC-driven cancer cell lines seem to be particularly
susceptible to this drug combination23. In our experiments, we
interrogated hallmark pathways and perturbation gene sets24,
which validated our MRT SMARCB1+ model, as we found
enrichment for SWI/SNF-related perturbation gene sets upon
SMARCB1 reconstitution (e.g. SNF5 (SMARCB1) and subunits of
Fig. 1 MRT are phylogenetically closely related to neural crest-derived Schwann cells. A Phylogenetic tree representing the somatic genetic relation of a
renal MRT and normal tissues. Percentages: clone size in tissues. Numbers inside circles: mutation burden within cluster. Red or white coloured rectangles:
SMARCB1 mutations status (red=mutant; white=wild type). LOH: loss of heterozygosity. H&E (B) staining of biopsies and INI1 (C) immunostaining,
showing INI1 negative Schwann cells in hilum biopsy 2. Scale bars= 100 µm. D Pattern of positive INI1 staining in Schwann cells of normal nerve sheath
from control hilar regions of two independent donors. Scale bars= 100 µm. E Phylogenetic tree representing the somatic genetic relation of an extradural
(spinal) MRT and normal tissues. Embryonic clusters of mutations are denoted (a–d). The annotation otherwise follows A. H&E staining (F), clone size of
the different mutational clusters (a–d, G), and INI1 immunostaining (H) of dorsal nerve root, ventral nerve root, tumour and (I) bone marrow of the same
donor. The latter showing positive INI1 staining. Scale bars= 100 µm.
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polycomb repressive complexes25) (Supplementary Fig. 6e, f).
Further, we found that MYC target genes were strongly down-
regulated upon SMARCB1 re-expression (Supplementary Fig. 6e, h).
This was mimicked by combined HDAC/mTOR inhibition, sig-
nificantly more strongly than by single-agent treatment (Supple-
mentary Fig. 6i). Further examination of differentially expressed
genes showed that identified pathways are largely shared between
SMARCB1 reconstitution and combination treatment (Supple-
mentary Fig. 6g, Supplementary Data 3). Together, these analyses
identify combined HDAC/mTOR inhibition as pharmacological
mimics of SMARCB1 reconstitution that prohibit proliferation and
induce differentiation in MRT.
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Discussion
We investigated the origin of MRT by combining phylogenetic
and transcriptional analyses with experiments in model systems.
Our findings indicate that MRT arise from the neural crest en
route to differentiating to mesenchyme and suggest combined
mTOR / HDAC inhibition as a therapeutic hypothesis.
Previous investigations into the origin of MRT have built on
transcriptional and epigenetic analyses of MRT. Despite the genetic
uniformity of intra- (AT/RT) and extracranial rhabdoid tumours,
with SMARCB1 loss being the sole recurrent genetic driver, such
analyses have revealed phenotypic, transcriptomic and epigenetic
variation in rhabdoid tumours, collectively showing neural and/or
mesenchymal differentiation of MRT7,8,26,27. Our phylogenetic
analyses now firmly place the root of MRT in a lineage with neural
crest-derived Schwann cells. The varied phenotype of MRT may
thus be explained by the ability of neural crest lineages to generate
cells across the boundaries of mesoderm and ectoderm. Modelling
attempts of rhabdoid tumours in mice have shown that the timing
of Smarcb1 loss during development is critical for the formation of
tumours6,28. It is interesting to note that in our study some mor-
phologically normal Schwann cells partly harboured the somatic
genome of MRT, including homozygous loss of SMARCB1 in some
cells. This would suggest that SMARCB1 loss on its own may not
suffice to generate tumours, or to prevent normal cellular differ-
entiation. This proposition is further corroborated by the wide
spectrum of tumours, including more benign entities, such as
Schwannomas, that pathogenic germline mutations in SMARCB1
(and related genes) predispose to29. Taken together, therefore,
factors other than embryological timing of disruption of SMARCB1
would seem to influence tumour formation in humans.
A unique feature that distinguishes childhood from adult
cancers is the fetal origin of paediatric tumours. The devel-
opmental programmes that underpin the aberrant differ-
entiation of cancer cells may lend themselves as therapeutic
target5. A precedent for this notion is the clinical use of reti-
noic acid derivatives as maturation treatment of neuro-
blastoma (https://clinicaltrials.gov/ct2/show/NCT01704716). It
is, however, challenging to devise maturation treatments, as
conventional readouts employed in high-throughput genetic or
drug screens, such as viability or proliferation, may not
necessarily capture differentiation states. We employed a novel
strategy here, by defining, in quantitative molecular terms, the
target state of MRT differentiation, as defined through
SMARCB1 reconstitution. We then used in silico matching of
target state and drug effects to search for agents that mimic
genetic SMARCB1 reconstitution. Our approach represents a
specific (biased) search for agents that elicit a predefined
transcriptional effect (in our case MRT maturation). Therefore,
although it lacks the power of unbiased drug screens to dis-
covering the unknown, our approach can be a focused path to
drug discovery, when the target state can be defined in quan-
titative, molecular terms.
Studies of rare tumours, such as MRT, that rely on access to
fresh material and detailed sampling are invariably small, even
when conducted across large consortia, such as ours. Therefore,
as the size of the biobank of MRT organoids grows with time, we
will have to re-examine our observations in larger cohorts.
Moreover, it will be important to examine the generalisability of
our findings to other tumours driven by the biallelic loss of
SMARCB1 and other members of the BAF chromatin-
remodelling complex, in particular AT/RT which are considered
to be the intracranial counterpart of MRT.
MRT remains one of the most aggressive childhood cancers,
which often rapidly progresses despite intense cytotoxic treat-
ment. It would therefore seem attractive to immediately try
combined mTOR / HDAC inhibition in the treatment of MRT.
However, what may seem to be a harmless differentiation agent
in vitro, may have severe adverse effects on postnatal develop-
ment in children5. For instance, a phase II trial on using a sonic
hedgehog (SHH) inhibitor in children with SHH medullo-
blastoma was terminated because of the induction of widespread
growth plate fusions30. Nevertheless, we would suggest that the
therapeutic hypothesis our findings formulate, merits further
evaluation. More broadly, our study defines a nimble blueprint
for quantitative approaches to the discovery of maturation targets
which is applicable across childhood cancer.
Fig. 2 SMARCB1 reconstitution drives MRT differentiation. A Schematic representation of SMARCB1 reconstitution in patient-derived MRT organoids and
subsequent single-cell transcriptome comparison to fetal mouse neural tube and neural crest cell types. Branching tree represents differentiation
trajectories of mouse neural crest. Abbreviations are indicated. B Representative immunofluorescence images of MRT control (C) and SMARCB1+ (S)
organoids. White: DAPI (nuclei), red: phalloidin (membranes), green: MMP2 (mesenchymal marker). Scale bars equal 50 µm. C UMAP representation of
single cells from MRT control (grey) or SMARCB1+ (green) organoid lines (60T control/SMARCB1+: 8059/425 cells, 78T control/SMARCB1+: 3195/806
cells, 103T control/SMARCB1+: 2694/953 cells). D Dot plots represent similarity of MRT control (circles) or SMARCB1+ (squares) cells to neural crest
differentiation trajectories. Colours represent the average probability (prob) that the MRT cells are similar to the indicated neural crest cell type (predicted
similarity score estimated by logistic regression12). Changes in similarity score between control and SMARCB1+ cells were assessed for cell types with
average similarity score >0.5. P values were calculated using an unpaired Student’s t test (two-tailed): *<1e−3, **<1e−9, ***<1e−15 (−log10 (p value): 60T
D= 45, S= 27, M2= 66, ME= 3.7; 78T NT= 9, D= 54, M1= 14, S= 22, M2= 4.4; 103T D= 198, EM= 40, S= 7.8, M2= 314, ME= 3.2). E Stacked bar
plot represents relative frequencies of single-cell annotations for MRT control (−) and SMARCB1+ (+) organoids, showing a consistent conversion of
neural to mesenchymal signals. Cell type annotation was assigned for each single-cell based on the highest similarity score. Colours represent neural crest
cell types depicted in Fig. 2a. Cell type migratory2 (M2) was assigned as either migratory mesenchyme (ME(M2)) or migratory autonomic (A(M2)) based
on the highest similarity score. The relative frequency of the mesenchymal/autonomic (ME/A) branch was compared between control and SMARCB1+
organoids for each patient line. P values were calculated using a chi-square test: *<0.01, ***<1e−15 (p value: 60T= 0.0048; 78T= 4.9e−48; 103T=
1.0e−32). F Dot plot shows expression levels (exp) of mesenchymal marker MMP2 for MRT control (−) and SMARCB1+ (+) organoids for each patient
line. Colour-code from grey to red refers to average MMP2 transcript levels (unique molecular identifier (UMI)). Dot size refers to the percentage of cells
(pct) showing MMP2 expression. G Box plot representation of gene module scores for MRT control (grey) and SMARCB1+ (green) single cells (n= 60T
control/SMARCB1+: 8059/425 cells; 78T control/SMARCB1+: 3195/806 cells; 103T control/SMARCB1+: 2694/953 cells), showing consistent
upregulation of mesenchymal/autonomic differentiation genes for SMARCB1+ cells. Box plots indicate median (middle line), 25th and 75th percentile
(box). Whiskers represent the range excluding outliers (dot). Module scores were generated by averaging gene expression levels per set of genes. Gene
sets include marker genes for either sensory (S) or mesenchymal/autonomic (ME/A) differentiation branches, distinguishing early and late differentiation
genes. Module scores were assessed by comparing control and SMARCB1+ cells. P values were calculated using an unpaired Student’s t test (two-tailed):
*<1e−3, **<1e−9, ***<1e−15 (−log10 (p value) ME/A late 60T= 28, 78T= 64, 103T= Inf; ME/A early 60T= 77, 78T= 134, 103T= Inf; S early 60T=
5.6, 78T= 72, 103T= 54; S late 60T= 28, 78T= 16, 103T= 11).
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Methods
Ethics statement. Tumour and normal tissues used for genetic lineage tracing
(Supplementary Table 1) were obtained as part of the SIOP2001 study approved by
the medical ethical committees of the institutes involved (Ethical Committee Uni-
versity Leuven (Belgium), Medical ethical committee of the Erasmus Medical Centre
Rotterdam (the Netherlands)), or were obtained from the Children’s Cancer and
Leukaemia Group (UK) Tissue Bank. Informed written consent was provided by all
patients and/or guardians.
Whole-genome sequencing. DNA was extracted from either formalin-fixed
paraffin-embedded (FFPE) tissues or fresh frozen tumour or tissue samples. Short
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insert (500 bp) genomic libraries were constructed and 75 base pair (FFPE) or 150
base pair (frozen) paired-end sequencing clusters were generated on either the
Illumina HiSeq X or the Illumina NovaSeq platform according to Illumina no-PCR
library protocols. An overview of samples and sequencing variables, including the
average sequence coverage, is shown in Supplementary Table 1.
DNA sequence processing and mutation calling. DNA sequences were aligned
to the GRCh37d5 reference genome using the Burrows–Wheeler algorithm (BWA-
MEM)31. Single-nucleotide variants (SNVs) were called against the reference
genome using CaVEMan32. Beyond the standard post-processing filters of
CaVEMan, we removed variants affected mapping artefacts associated with BWA-
MEM by setting the median alignment score of reads supporting a mutation as
greater than or equal to 140 (ASMD ≥ 140) and requiring that fewer than half of
the reads were clipped (CLPM= 0).
Across all samples from one patient, we recounted the SNVs that were called in
any sample from the patient, using minimum values for read mapping quality (30)
and base quality (25). Germline and somatic variants were distinguished using a
one-sided binomial exact test on the number of variant reads and depth present in
the matched tissue samples. Resulting p values were corrected for multiple testing
with the Benjamini–Hochberg method33 and a cut-off was set at q < 10−5. Variants
were also filtered out if they were called in a region of consistently low (<15×) or
high depth (>50×) across all samples from one patient. These thresholds were
halved for the X and Y chromosomes in the male patient, PD42923. Using a beta-
binomial model of a site-specific error rate as previously employed16, we
distinguished the true presence of SNVs from support due to sequencing errors and
noise. All shared SNVs were further visually inspected using the genome browser,
Jbrowse34. See Supplementary Data 1 for SNV calls of PD42923 and PD46555,
respectively. CNVs were called using ASCAT35 and Battenberg36. Structural
variants were called using BRASS37 (Supplementary Data 1).
Clustering and classification of SNVs. To reconstruct the clonal composition of
normal tissues, we employed an N-dimensional Bayesian mixture model based on
the Dirichlet process38. Briefly, SNVs were clustered based on their distribution of
variant supporting reads and total depth across all (N) samples. Therefore, it
naturally accounts for differences in coverage between samples and does not rely
on hard VAF cut-offs. Cellular contributions of mutational clusters were reconciled
into a tree based on the pigeon hole principle, i.e. the sum of contributions in
daughter branches can never exceed that of the parental one.
Organoid culture. MRT organoids were previously established and characterised17. In
brief, organoid line 60T, 78T and 103T (Supplementary Table 2) were seeded in growth
factor-reduced BME (Trevigen) and cultured in organoid medium (Advanced DMEM/
F12 (Gibco) containing 1× Glutamax, 10mM HEPES and antibiotics (AdDF+++),
supplemented with 1.5% B27 supplement (Gibco), 10% R-spondin-conditioned med-
ium, EGF (50 ng/ml, Peprotech), FGF-10 (100 ng/ml, Peprotech), N-acetylcysteine
(1.25mM, Sigma), Rho-kinase inhibitor Y-27632 (10 µM, Abmole) and A83-01 (5 µM,
Tocris Bioscience)) as described in ref. 17. For SMARCB1 re-expression, MRT orga-
noids were lentivirally transduced39 with pLKO.1-UbC-luciferase-blast40 or pLKO.1-
UbC-hSMARCB1-blast lentiviruses. After 2 days, 10 µg/ml blasticidin was added to the
culture medium. For DNA methylation profiling, immunofluorescence and mRNA
sequencing experiments (bulk as well as single-cell), organoids were harvested 4 days
after lentiviral infection. For cell viability measurements, organoids were harvested
7 days after lentiviral infection and viability was measured using CellTiter-Glo 3D
reagent (Promega) according to manufacturer’s instructions on a Fluorstar Omega
plate reader. HDACi in MRT organoids was performed using 1 µM entinostat (Sell-
eckChemicals) or 1 µM vorinostat (MedChemExpress), added 2 days after seeding
single cells. For HDACi and mTORi immunofluorescence and mRNA-seq experi-
ments, 1 µM vorinostat and/or 2 nM sirolimus (MedChemExpress) were added to the
organoid cultures 2 days after seeding single cells. Cells were harvested 4 days after
addition of the drugs.
Histology. Tissues were fixed in 4% paraformaldehyde, dehydrated and embedded
in paraffin. Immunohistochemistry was performed according to standard protocols
on 3–4 µm sections. Sections were subjected to H&E and immunohistochemical
staining with the following primary antibodies: INI1 (BD Transduction Labora-
tories, 612111, 1:400).
Immunofluorescence. Immunofluorescence experiments were performed as
described in ref. 41, using DAPI (Thermo Fisher, D9542, 1:1000), Alexa Fluor 647
Phalloidin (Thermo Fisher, A22287, 1:200) and primary antibody MMP2 (Thermo
Fisher, MA5-13590, 1:500). High-resolution 3D imaging was performed in µ-Slide
8 Well chambers (IBIDI, 80826) using the Leica SP8 confocal microscope and a
20× water immersion objective. Organoids were imaged in 3D by acquiring z-
stacks, which were visualised by maximum intensity projections. Acquisition set-
tings for MMP2 were fixed across experiments.
DNA methylation profiling. Genomic DNA was extracted from MRT organoids
using the ReliaPrep gDNA Tissue Miniprep System (Promega) according to the
manufacturer’s protocol. DNA methylation profiles were established using Illumina
Human MethylationEPIC BeadChip arrays at the German Cancer Research Center
(DKFZ) Genomics and Proteomics Core Facility according to the manufacturer’s
protocol. DNA methylation data were analysed as described in ref. 26. Organoid
methylation data were co-clustered with previously published DNA methylation
data of AT/RT and MRT7.
Single-cell mRNA sequencing. MRT organoids were dissociated into single-cell
suspensions using TrypLE Express (Thermo Fisher) supplemented with Y-27632
(10 µM, Abmole) and subsequently processed on the Chromium 10X Genomics
controller as previously described10. Cell viability was estimated using Trypan Blue
solution (Thermo Fisher, 15250061), ranging from 38 to 65% viable cells. For 78T
and 103T samples, single cells were mixed pre-loading in a one to one ratio.
Libraries were produced according to the manufacturer’s protocol and sequenced
on Illumina platforms (HiSeq4000 or NextSeq500).
Mapping, quantification, quality control and demultiplexing of single-cell
mRNA-seq data. Raw sequencing data were aligned to the reference genome
(GRCh38) and quantified with cell Ranger 2.0.2 pipeline42 for 60T samples
(sequencing was done with Chromium single-cell 3′ v2 chemistry) and cell Ranger
3.0.3 pipeline for mixed 78T and 103T samples (sequencing was done with
Chromium single-cell 3′ v3 chemistry), producing a table of counts of unique
molecular identifiers (UMI) for each single-cell and gene with sequencing depth
Fig. 3 Combined HDAC/mTOR inhibition mirrors SMARCB1 reconstitution. A Overview of methodology used for discovery of potential differentiation
therapeutics. B Representative immunofluorescence images of MRT organoids treated with DMSO control or a combination of vorinostat (HDACi, 1 µM)
and sirolimus (mTORi, 2 nM). White: DAPI (nuclei), red: phalloidin (membranes), green: MMP2 (mesenchymal marker). Scale bars equal 50 µm.
C Heatmaps represent gene expression values (n= 2 independent experiments) of MRT control or SMARCB1+ organoids, or MRT organoids treated with
vorinostat (HDACi, 1 µM) or both vorinostat and sirolimus (combination,1 µM/2 nM). Heatmaps are subset for genes differentially expressed upon
SMARCB1 re-expression (Supplementary Data 3). Genes are ordered by the average mRNA changes induced by SMARCB1 re-expression and treatment.
Colour-code represents gene expression values scaled by gene. Pearson correlation coefficients (corr.) were generated by comparing mRNA changes
induced by either SMARCB1 re-expression or HDACi/combination treatment. P values are indicated for Pearson’s correlation tests (two-tailed): ***<1e−15
(−log10 (p value): Combi 60T= 217, 78T= Inf, 103T= 221; HDACi 60T= 268, 78T= 306, 103T= 192). D Schematic overview of the dose-response
matrix setup to find synergy between HDAC (vorinostat) and mTOR (sirolimus) inhibitors in MRTs. E Graphs show zero interaction potency (ZIP) scores
that indicate either synergistic (red) or antagonistic (blue) effects of combination treatment. ZIP scores are generated by calculating the observed deviation
from a reference model that assumes drugs are non-interacting (synergy when ZIP > 10%51). The dashed rectangles highlight the drug concentration
ranges where synergy between the two drugs is the strongest. Source data are provided as a Source Data file. F Schematic overview of the regrowth assay.
G Bar graphs represent cell viability values normalised to timepoint 1 (T1) DMSO controls for each MRT or normal kidney organoid line. Mean and SD
(error bars) of independent experiments (dot) are indicated (n= 60T/103T: 3, 78T mTOR/HDAC 1 µM/Combi 2 nM 1 µM: 6, 78T HDAC 3 µM/Combi
2 nM 3 µM: 4. normal kidney: 7). Each independent experiment is an average of four technical replicates. Source data are provided as a Source Data file.
Additional effect of combination treatment on cell viability was determined by comparing combination (T2) with HDACi (T2) treatment. Regrowth
capability was assessed by comparing T2 to T1. P values were calculated using a paired ratio Student’s t test (two-tailed): *<0.05, **<0.01, ***<0.001
(p value: Combi 1 µM T1 vs. HDACi 1 µM T1 60T= 0.020, 78T= 0.012; Combi 3 µM T2 vs. Combi 3 µM T1 78T= 0.013, normal kidney donor 1= 2.5e−5,
donor 2= 1.8e−5).
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(average reads/cell) for 60T control (35k), SMARCB1+ (490k), 78T and 103T
mixed control (34k) and SMARCB1+ (44k). Demultiplexing of 78T and 103T was
performed with demuxlet software43 with default parameters using genotype data
of patient line 78T and 103T17. Gene expression matrices were further processed
with python package scanpy version 1.4.4.post144. Poor quality cells were filtered
out based on a low number of genes (<200 detected genes) and high mitochondrial
content (>10% for 60T and >20% for 78T and 103T). Cells were filtered based on
SMARCB1 transcript counts. For MRT control samples, cells were removed with
SMARCB1 > 0. For MRT SMARCB1+ samples, cells were removed with
SMARCB1= 0. Doublets were detected and excluded with python package scrublet
version 0.2.145 with default parameters. Demultiplexing of organoid lines 78T and
103T was performed based on cluster assignment provided by demuxlet. In
addition, single-cell outliers for 78T and 103T were removed based on low coverage
(detected UMIs <1500) or high counts (more than 60,000 for 78T and 50,000 for
103T). All the scripts used for filtering and quality control are listed in the “Code
availability” section. Sample metadata are provided in Supplementary Table 3.
Clustering and module scores. For UMAP visualisation and single-cell clustering,
raw gene expression matrices of filtered cells were processed using R package
Seurat version 3.1.4 and standard analysis pipelines46. Downstream analysis was
performed for all single cells combined (Fig. 2f, g, Supplementary Fig. 3d, e) or
separately for each patient line (Fig. 2c, Supplementary Figs. 4b, 5a–f) and included
the following steps. Data normalisation of raw counts was performed using R
package sctransform47 version 0.2.1 integrated in Seurat. The single command
“SCTransform” was applied, which replaces the Seurat commands “Normal-
izeData”, “ScaleData” and “FindVariableFeatures”. Counts were normalised using
the standard normalisation method “LogNormalize” with scaling factor 10,000.
Confounding sources of variation were removed by regressing out mitochondrial
content (“PercentageFeatureSet” for gene names starting with “MT”). Single cells
were scored for cell cycle (“CellCycleScoring”) which was additionally regressed out
to correct for unwanted cell cycle effects. Subsequently, we performed principal
component analysis (“RunPCA”) using highly variable features (3000 genes using
default parameters), followed by dimensionality reduction (“RunUMAP”). Inclu-
sion of principal components was based on a scree plot (“ElbowPlot”) by placing
the cut-off at the elbow of the curve (Combined: 1-18, 60T: 1–15, 78T: 1–17, 103T:
1–15). Clusters were determined by Louvain graph-based clustering, performed
separately for each patient line (“FindNeighbours” and “FindClusters”). The
optimal clustering resolution was identified by calculation of average silhouette
widths for a series of resolutions (Supplementary Fig. 5b). Differentially expressed
genes for control and SMARCB1+ single cells were determined using “FindMar-
kers” (Supplementary Data 2). Marker genes defining single-cell clusters were
determined using “FindAllMarkers” (Supplementary Data 2). P values were cal-
culated using a Wilcoxon Rank Sum test and were corrected for multiple testing.
Module scores were calculated (“AddModuleScore”) on a combined normalised
dataset of all patient lines for inter-organoid comparisons (Fig. 2g), or separately
for each patient line for assessment of single-cell clusters (Supplementary Fig. 5f).
Neural crest branch-specific gene sets include marker genes that separate sensory
and autonomic/mesenchymal branches, further specifying late genes (upregulated
in differentiated cells) and early genes (upregulated in progenitor and differentiated
cells), as described in ref. 18. Mouse genes without human orthologue were
excluded. All the scripts used for clustering and module scores are listed in the
“Code availability” section.
Logistic regression. The probability that the transcriptome for each single MRT
cell is similar to each mouse neural crest cluster was estimated with logistic
regression in R, as described previously12. The fetal mouse neural crest dataset18
was extracted from GEO (accession number GSE129114) selecting for the fol-
lowing cells: Wnt1 E8.5 whole embryo, Wnt1 E9.5 trunk and Wnt1 E10.5 tail.
Cluster assignment for each cell in the combined dataset was extracted from
Supplementary Table 918. The second dataset of fetal mouse organogenesis19 was
extracted from GEO (accession number GSE119945), selecting cells from early
mesenchymal, glial and neural trajectories with the following cell annotations
(Main_cell_type field in GSE119945_cell_annotate.csv.gz file): Early mesenchyme,
Intermediate Mesoderm, Connective tissue progenitors, Schwann cell precursor,
Sensory neurons, Neural Tube, Neural progenitor cells, Radial glia. Mouse gene
symbols were converted to their human orthologues using biomaRt version 2.40.4
in R. Raw transcript counts for human genes that mapped to multiple mouse genes
were excluded from further analysis. The logistic regression model was trained on
the neural crest dataset with R package cv.glmnet, and was used to generate
probability scores for the MRT cells.
Bulk mRNA sequencing. Total RNA was extracted using Trizol reagent (Thermo
Fisher) and quality-checked using Bioanalyzer2100 RNA Nano 6000 chips (Agi-
lent). Sequencing libraries were prepared using the NEBNext® Ultra™ RNA Library
Prep Kit (New England Biolabs) according to the manufacturer’s protocol.
Stranded paired-end sequencing (PE150) was performed on the Illumina HiSeq or
Illumina NovaSeq platform by Novogene (Hong Kong).
For data analysis, TruSeq3 adapters were removed from reads using
Trimmomatic version 0.36.5, followed by sliding window trimming to trim low-
quality bases (<20 average quality over four bases). Unpaired reads were removed
for subsequent steps. Reads were mapped to the reference genome (GRCh38) using
STAR version 2.6.0 and assigned using featureCounts version 1.6.3 based on gene
annotation GENCODE version 28. Gene expression changes were calculated using
the R package DESeq2 version 1.22.1, and differentially expressed genes were
determined by the Wald significance test with multiple-testing correction (FDR <
0.01 and fold change > 2) (Supplementary Data 3). The overlap of differentially
expressed genes for three patient lines was tested using a multi-set hypergeometric
test48. For SMARCB1+ programme validation, z scores were generated from gene
expression data acquired from a paediatric renal tumour biobank17 and
downloaded from the GTEx portal (https://gtexportal.org/home/datasets,
GTEx_Analysis_2017-06-05_v8_RNASeQCv1.1.9_gene_median_tpm.gct.gz). For
PCA, gene counts were normalised by variance stabilising transformation (VST,
DESeq2), and principal components were generated using prcomp in R. For
heatmaps, VST counts were corrected for batch effect using R package limma
version 3.38.3. Heatmaps were generated using R package pheatmap version 1.0.12,
scaling was applied by gene. Gene set enrichment analysis49 for hallmark and
perturbation24 gene sets was performed using the R package clusterProfiler version
3.10.1. Genes were ranked according to SMARCB1-induced mRNA changes that
were averaged for 60T, 78T and 103T. For the comparison of SMARCB1 re-
expression and combination treatment, unordered gene sets (generated by
intersection of differentially expressed genes, Supplementary Data 3) were
submitted for hallmark pathway enrichment analysis.
Connectivity map. A connectivity map was generated by submitting the top 100
genes upregulated by SMARCB1 re-expression in MRT organoids to the online
CLUE query tool20. Input genes were selected based on significantly upregulated
genes overlapping for 60T, 78T and 103T. Genes were ranked based on average
gene expression changes. Connectivity map drugs were ranked by the median
percentage of similarity.
Western blot. Western blot on MRT organoids was performed as described in
ref. 50 using the following antibodies:
SMARCB1/INI1 A-5 (Santa Cruz Biotechnology, sc-166165, 1:1000), beta-
tubulin H235 (Santa Cruz Biotechnology, sc-9104, 1:1000).
Drug testing and synergy assays. MRT organoids were harvested and washed in
ice-cold AdDF+ ++. Organoids were subsequently filtered using a 70 µm cell
strainer (Falcon) and resuspended in 5% BME in medium. Next, ~500 organoids
were plated using the Multi-dropTM Combi Reagent Dispenser on repellent black
384-well plates (Corning) to which medium with drugs were added using the Tecan
D300e Digital Dispenser. Four technical replicates were included in each experi-
ment. Five days after adding drugs, cell viability was measured using CellTiter-Glo
3D reagent (Promega) according to the manufacturer’s instructions. Results were
normalised to the DMSO vehicle (100%). Dose-response curves were generated by
nonlinear regression (curve fit) using GraphPad Prism v8.0.2 Synergy scores were
generated by R package synergyfinder version 1.8.0 using the ZIP method51.
Regrowth assay. MRT and normal kidney organoids were dissociated into single
cells using mechanical disruption and TrypLE Express (Invitrogen, 12605036), and
5000 cells were seeded in 5 µl BME droplets in two separate flat-bottom 96-well
plates (Corning). Drugs were added either one (78T), two (60T and 103T) or 3
(normal kidney donor 1 and 2) days after seeding to normalise for growth rate.
Vorinostat and sirolimus concentration were selected based on the highest synergy
score for each patient line. Sirolimus concentration was fixed for all experiments
(2 nM), while vorinostat concentration varied (60T: 1 µM, 78T: 1 µM, 103T: 3 µM).
Both concentrations of vorinostat (1 and 3 µM) were tested for 78T and normal
kidney organoids. Five days after addition of the drugs, cell viability was measured
in the first plate using CellTiter-Glo 3D reagent (Promega) according to the
manufacturer’s instructions. In the second plate, medium was exchanged for
medium without drugs. Five days after drug removal, cell viability was measured.
Results were normalised to the DMSO vehicle of T1 (100%).
Statistics and reproducibility. For Fig. 1, genetic lineage tracing experiments were
performed for n= 2 independent donors. Images of Fig. 1b–d, i correspond to the
regions that were sampled for genetic lineage tracing experiments, which were
imaged before and after the collection of material (n= 2). Representative images of
Fig. 1d were derived from n= 2 independent donors, for which at least n= 3 areas
with nerve tissue were assessed for each donor. For Fig. 2b and Supplementary
Fig. 4a, c, d, representative images were derived from n= 3 independent immu-
nofluorescence experiments. The western blot image in Supplementary Fig. 3a was
representative of n= 3 independent experiments. For Fig. 3b, representative images
were derived from n= 2 independent immunofluorescence experiments. For
Supplementary Fig. 7a, b, representative images were derived from at least n= 3
independent experiments.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21675-6 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:1407 | https://doi.org/10.1038/s41467-021-21675-6 | www.nature.com/naturecommunications 9
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Raw sequencing data have been deposited in the European Genome-phenome Archive
(EGA, www.ebi.ac.uk/ega/). Accession numbers are EGAD00001006574 (bulk mRNA-
seq;) and EGAD00001006296 (WGS and scRNA-seq;). The data are available under
restricted access. Access can be granted by contacting biobank@prinsesmaximacentrum.
nl (EGAD00001006574) or datasharing@sanger.uk.ac (EGAD00001006296). DNA
methylation data are available under GEO (www.ncbi.nlm.nih.gov/geo/) accession
number GSE161814. Processed scRNA-seq data (derived from raw sequencing data
deposited under accession number EGAD00001006296) are available at https://github.
com/kheleon/mrt-paper52. Content includes filtered_gene_bc_matrices and
filtered_feature_bc_matrix folders from cellranger output. The fetal mouse neural crest
dataset18 was extracted from GEO (www.ncbi.nlm.nih.gov/geo/, accession number
GSE129114). The second dataset of fetal mouse organogenesis19 was extracted from GEO
(www.ncbi.nlm.nih.gov/geo/, accession number GSE119945). Gene expression data of
the paediatric renal tumour biobank17 was extracted from EGA (www.ebi.ac.uk/ega/,
accession number EGAD00001005318 and EGAD00001005319). Gene expression data of
normal tissues was extracted from GTEx portal (https://gtexportal.org/home/datasets,
GTEx_Analysis_2017-06-05_v8_RNASeQCv1.1.9_gene_median_tpm.gct.gz). The
remaining data are available within the Article, Supplementary Information,
Supplementary Data and Source Data provided with this paper or are available from the
authors upon request. Source data are provided with this paper.
Code availability
Jupyter notebooks for processing of scRNA-seq data are available at https://github.com/
kheleon/mrt-paper52.
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